You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Allergies and anaphylaxis

Omalizumab for previously treated chronic spontaneous urticaria

  • Technology appraisal guidance
  • Reference number: TA339
  • Published:  08 June 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final appraisal determination document

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final appraisal determination document Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final appraisal determination document
11 March 2015
(252.64 Kb 13 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 06 March 2015

Back to top